Morphogenesis, Inc. and CohBar, Inc. Enter into Definitive Merger Agreement to Advance an Innovative Late-stage Clinical Immuno-oncology Pipeline of Therapies to Overcome Resistance to Cancer Immunotherapy
The companies hosted a joint webcast on May 23, 2023, to discuss the transaction.
We are a Phase 2/3 clinical-stage biotechnology company developing novel personalized cancer vaccines and tumor microenvironment modulators to overcome resistance to current immunotherapies. Our mission is to improve the lives of patients by developing novel therapies to overcome the underlying mechanisms by which tumor cells escape immune recognition.
About Us
We are advancing two proprietary technologies to overcome:
Our approach enables us to target large unmet medical needs in a range of cancers, including Merkel Cell Carcinoma, B-Cell Malignancies, Myelodysplasia (Myelodysplastic Syndromes) and Acute Myeloid Leukemia.
Our PipelineOur IFx technology is designed to activate the immune system to target and attack tumor cells by making tumor cells look like bacteria. Our approach provides a potent systemic response against all neoantigens in a patient’s tumor.
Learn MoreOur tumor microenvironment modulators are designed to address one of the primary causes of acquired resistance to immunotherapies, including checkpoint inhibitors or cellular therapies like CAR-T. Leveraging novel bi-functional antibody drug conjugates (ADCs), we are targeting a novel delta receptor on myeloid derived suppressor cells (MDSCs), which comprise 80% of cells in the tumor microenvironment and are responsible for suppressing the immune system’s attack against the tumor.
Learn More